MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities and sale of
investment securities
$1,184,097K
Proceeds from exercise of
stock options and...
$40,611K
Net cash provided by
(used in) investing...
$173,908K
Net cash provided by
financing activities
$40,611K
Canceled cashflow
$1,010,189K
Net change in cash,
cash equivalents and...
-$163,403K
Canceled cashflow
$214,519K
Stock-based compensation
$91,024K
Accounts payable and
accrued expenses,...
$28,983K
Depreciation and
amortization
$3,890K
Noncash lease expense
$3,014K
Loss on disposal of
property and equipment
-$50K
Product
$5,420K
License And Service
$2,276K
Purchases of investment
securities
$1,004,427K
Purchases of property and
equipment
$5,762K
Net cash used in
operating activities
-$377,922K
Canceled cashflow
$126,961K
Total other income,
net
$51,632K
Revenue
$7,696K
Net loss
-$465,317K
Canceled cashflow
$59,328K
Prepaid expenses and
other assets
$16,511K
Accretion of purchase
discounts and...
$15,425K
Operating lease
liabilities
-$3,181K
Inventory
$2,022K
Deferred revenue
-$1,835K
Trade accounts
receivable
$592K
Total research and
development expenses
$332,058K
Selling, general and
administrative
$191,331K
Cost of product
revenue
$1,076K
Income tax expense
$180K
Research and development
personnel expenses
$102,677K
Paltusotine
$68,337K
Research and development
stock-based compensation
$50,344K
Atumelnant
$48,131K
Other research and
development programs
$33,322K
Other research and
development
$29,247K
External selling,
general and...
$90,013K
Selling, general and
administrative personnel...
$60,638K
Selling, general and
administrative stock-based...
$40,680K
Back
Back
Cash Flow
source: myfinsight.com
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)